MarketPulse

LEQEMBI IQLIK

2 articles
BenzingaBenzinga··Vandana Singh

Biogen Rallies on Pipeline Progress Despite Leqembi Review Delay

Biogen shares rise 1.06% to $193.40 despite FDA extending Leqembi review to August 2026, offset by $5.6B Apellis acquisition and Spinraza approval momentum.
APLSBIIBbiotechApellis Pharmaceuticals
GlobeNewswire Inc.GlobeNewswire Inc.··Eisai Co., Ltd. And Biogen Inc.

FDA Extends Review of Eisai-Biogen's LEQEMBI Subcutaneous Formulation to August 2026

FDA extends LEQEMBI IQLIK subcutaneous review to August 2026 without raising approvability concerns, maintaining regulatory momentum for Eisai and Biogen's reformulated Alzheimer's treatment.
BIIBFDA approvalsubcutaneous injection